Hadassah

BrainStorm Stem Cell Therapy for ALS is Fast-Tracked to New Phase

Thursday, Jan 24 2013

The ALS PhaseI/II safety trial of Brainstorm Cell Therapeutics' NurOwn stem cell therapy has been fast tracked to a Phase IIa dose-escalating trial by Israel's Ministry of Health and will be launched "immediately" at the Hadassah Medical Center, reports this leading developer of adult stem cell technologies for neurodegenerative diseases.

Prof. Dimitrios Karussis, Principal Investigator of BrainStorm's Phase I/II trial and head of the Multiple Sclerosis Center at Hadassah, commented: "Based on the positive results we have seen for the first 12 patients, we are eager to begin the next stage of clinical testing, and are delighted that the Ministry of Health has given us the green light to proceed to Phase IIa."

"Acceleration to Phase IIa will save us critical time, enabling us to proceed much more quickly with achieving our goal of developing an effective treatment for ALS," said Dr. Adrian Harel, BrainStorm's Chief Executive Officer.

In the Phase IIa trial, the second group of 12 patients from the initial cohort of 24 will receive combined intramuscular and intrathecal administration of NurOwn cells in three cohorts, with increasing doses. The study participants, who have already been recruited, will be followed for three to six months after transplantation.

BrainStorm plans to expand its clinical development to the United States in 2013, pending approval by the Food and Drug Administration. The company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these medical facilities.

BrainStorm's NurOwn is a first-of-its-kind adult stem cell therapy for the treatment of neurodegenerative diseases derived from autologous bone marrow cells.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Feb 22 2017

Hadassah Medical Organization Performs Israel’s First Spina Bifida Fetal Surgery To Lessen Crippling Spinal Damage

History was made at Hadassah Ein Kerem Hospital in Jerusalem on Thursday, February 9 when a team of Israeli surgeons successfully operated on a 5-month-old fetus using a new procedure that only three doctors in the world can perform, to alleviate some of the crippling effects of Spina Bifida.

READ MORE ›
alt_text

Tuesday, Feb 21 2017

Hadassah Cardiologists Publicize Israel’s Dramatic Decrease in Cardiovascular Death

Prof. Emeritus Mervyn Gotsman and Prof. Israel Gotsman of Hadassah Hospital’s Heart Institute have coauthored an article which appeared in the European Heart Journal, highlighting the fact that “between 1998 and 2012, mortality from cardiovascular disease in Israel has fallen from 162 to 80 per 100,000 residents--a decrease of 50 percent.”

READ MORE ›
alt_text

Tuesday, Feb 21 2017

Ambassadors of Health for Heart Smart Living: A Unique Hadassah Program

Knowing that the workplace is where people spend vast quantities of time, the Hadassah Medical Organization’s Linda Joy Pollin Cardiovascular Wellness Center for Women launched a unique course to encourage heart healthy living—during the work day.

READ MORE ›
alt_text

Tuesday, Feb 21 2017

Hadassah Brings Health Empowerment to East Jerusalem

The increased incidence of diabetes in the Arab community, as well as the 60 percent higher rate of cardiovascular mortality among Arab women led the Hadassah Medical Organization’s Linda Joy Pollin Cardiovascular Wellness Center for Women to develop a community-based program to cultivate leadership that embraces and advocates for healthy living which will reduce diabetes in this population.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More